Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342117 · ClinicalTrials.gov registry record
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
A clinical trial, sponsored by SecuraBio.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04342117: Clinical Trial study, sponsored by SecuraBio.
NCT04342117 is a clinical trial that was terminated before completion, run by SecuraBio. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04342117 was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
Primary Outcome
Observe the effectiveness of the PI3K-inhibitor administered
Interventions
- DRUG duvelisib
- DRUG PI3K inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-23 |
| Est. Completion | 2020-12-31 |
Why NCT04342117 stopped before completion
NCT04342117 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which duvelisib is the first listed.
NCT04342117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04342117 about?
NCT04342117 is a clinical study titled "Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL". This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
What is the current status of trial NCT04342117?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-04-23. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04342117?
The interventions under investigation include: duvelisib (DRUG), PI3K inhibitor (DRUG).
Who is sponsoring clinical trial NCT04342117?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI